文献速递乳腺癌

基于毒性调整剂量的FEC化疗在早期乳腺癌中的随机研究

A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1).
PubMed 文献 · Eur J Cancer · 2018-03-20

SBG 2000-1是首个随机试验,比较基于毒性等级个体化调整剂量(无G-CSF支持)与基于体表面积标准剂量FEC化疗的疗效。共入组1535例早期乳腺癌患者,1052例随机分组。调整剂量组10年DDFS为79%,标准组77%,差异无统计学意义(HR 0.87,P=0.32);OS分别为82%和78%(HR 0.89,P=0.38)。

要点

  • 基于毒性调整剂量未能显著改善无远处疾病生存(DDFS)或总生存(OS)。
  • 所有疗效指标在调整剂量组均有数值上的优势,但未达统计学显著性。
  • 对于第一周期后白细胞减少0-2级的患者,增加剂量并未带来显著生存获益。

核心结论

  • 在低血液学毒性患者中,与标准体表面积剂量化疗相比,调整剂量化疗未显著改善DDFS或OS。

研究设计与样本

  • 随机对照试验,入组1535例早期乳腺癌患者,接受第一周期标准FEC方案。
  • 白细胞减少0-2级者随机接受6周期调整剂量FEC(N=524)或标准FEC(N=528)。
  • 白细胞减少3-4级者登记接受标准FEC(N=401)。

主要发现

  • 登记组(白细胞减少3-4级)的DDFS为79%,OS为82%。

关键数值与推荐

  • 调整剂量FEC中表柔比星剂量为75-90 mg/m2,环磷酰胺为900-1200 mg/m2。
  • 标准FEC剂量为氟尿嘧啶600 mg/m2、表柔比星60 mg/m2、环磷酰胺600 mg/m2。

临床怎么用

  • 对于第一周期标准FEC后白细胞减少0-2级的早期乳腺癌患者,基于毒性调整剂量未显示显著生存获益,不支持常规采用。

局限性

  • 调整剂量组未使用G-CSF支持,可能影响剂量强度。
  • 研究仅纳入低血液学毒性患者,结果不能推广至所有早期乳腺癌患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY AIM: Retrospective studies have demonstrated a worse outcome in breast cancer patients not developing leukopenia during adjuvant chemotherapy. The SBG 2000-1 is the first randomised trial designed to compare individually dosed chemotherapy without G-CSF support based on grade of toxicity to standard-dosed chemotherapy based on body surface area (BSA). METHODS: Patients with early breast cancer were included and received the first cycle of standard FEC (fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 600 mg/m2). Patients with nadir leukopenia grade 0-2 after first cycle were randomised between either 6 additional courses of tailored FEC with increased doses (E 75-90 mg/m2, C 900-1200 mg/m2) or fixed treatment with 6 standard FEC. Patients with grade 3-4 leukopenia were registered and treated with 6 standard FEC. Primary end-point was distant disease-free survival (DDFS). RESULTS: The study enrolled 1535 patients, of which 1052 patients were randomised to tailored FEC (N = 524) or standard FEC (N = 528), whereas 401 patients with leukopenia grade 3-4 continued standard FEC and formed the registered cohort. Dose escalation did not statistically significantly improve 10-year DDFS (79% and 77%, HR 0.87, CI 0.67-1.14, P = 0.32) or OS (82% and 78%, respectively, HR 0.89, CI 0.57-1.16, P = 0.38). Corresponding estimates for the registered group of patients were DDFS 79% and OS 82%, respectively. CONCLUSIONS: The SBG 2000-1 study failed to show a statistically significant improvement of escalated and tailored-dosed chemotherapy compared with standard BSA-based chemotherapy in patients with low haematological toxicity, although all efficacy parameters showed a numerical advantage for tailored treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lindman H, Andersson M, Ahlgren J, et al. A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1). Eur J Cancer. 2018. PMID: 29547834. doi:10.1016/j.ejca.2018.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。